Pancreatic Cancer Research

ResearcherJiangsu Province HospitalActive in the last 2 years

Min Tu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-1017-8825; OpenAlex author ID A5101602612, A5128334734. Sources: ClinicalTrials.gov.

Their work

Papers
26 (first author 1, last author 1)
Trials
1
Grants
0
Labs led
0
Collaborators
114
Papers, trials and grants by year

2013: 3 papers · 2014: 1 paper · 2015: 2 papers · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 4 papers · 2022: 3 papers · 2023: none · 2024: 2 papers, 1 trial · 2025: 4 papers · 2026: 3 papers

Papers 26

  1. First-line nanoparticle polymeric micellar paclitaxel with gemcitabine in metastatic pancreatic cancer: a single-arm, prospective, and exploratory study. Last author DOI 10.1093/gastro/goag034↗
  2. Long-term outcomes of upfront pancreatectomy with venous resection for pancreatic cancer: a single-center, retrospective analysis. Co-author DOI 10.1097/js9.0000000000003617↗
  3. Co-evolution of Oncogenic KRAS Signaling and LILRB high Macrophages Drives Pancreatic Cancer Recurrence Co-author DOI 10.64898/2026.03.05.709991↗
  4. LIM domain only 7: a novel driver of immune evasion through regulatory T cell differentiation and chemotaxis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41418-024-01358-7↗
  5. The feasibility and potential benefits of administering adjuvant chemotherapy in resected pancreatic cancer patients unable to promptly remove intraperitoneal … Co-author DOI 10.1186/s12885-025-14262-1↗
  6. Efficacy of second-line treatment for gemcitabine-refractory unresectable pancreatic cancer in a real-world setting. Co-author DOI 10.1186/s12885-025-14601-2↗
  7. Development and Validation of a Cell-Free DNA Fragmentomics-Based Model for Early Detection of Pancreatic Cancer. Co-author DOI 10.1200/jco.24.00287↗
  8. Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study. Co-author DOI 10.1200/jco.23.02313↗
  9. [Short-term outcomes of the TRIANGLE operation after neoadjuvant chemotherapy in locally advanced pancreatic cancer]. First author DOI 10.3760/cma.j.cn112139-20230615-000234↗
  10. Prevalence of Germline Sequence Variations Among Patients With Pancreatic Cancer in China. Co-author DOI 10.1001/jamanetworkopen.2021.48721↗
  11. CircSTX6 promotes pancreatic ductal adenocarcinoma progression by sponging miR-449b-5p and interacting with CUL2. Co-author DOI 10.1186/s12943-022-01599-5↗
  12. Identification of FEZ2 as a potential oncogene in pancreatic ductal adenocarcinoma. Co-author DOI 10.7717/peerj.12736↗
  13. Sub-adventitial divestment technique for resecting artery-involved pancreatic cancer: a retrospective cohort study. Co-author DOI 10.1007/s00423-021-02080-5↗
  14. Development and validation of a ferroptosis-related prognostic model in pancreatic cancer. Co-author DOI 10.1007/s10637-021-01114-5↗
  15. Development and validation of a ferroptosis-related prognostic model in pancreatic cancer Co-author DOI 10.21203/rs.3.rs-139597/v2↗
  16. CA9-Related Acidic Microenvironment Mediates CD8+ T Cell Related Immunosuppression in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.832315↗
  17. Linc01232 promotes the metastasis of pancreatic cancer by suppressing the ubiquitin-mediated degradation of HNRNPA2B1 and activating the A-Raf-induced MAPK/ERK… Co-author DOI 10.1016/j.canlet.2020.08.001↗
  18. HHLA2 is a novel immune checkpoint protein in pancreatic ductal adenocarcinoma and predicts post-surgical survival. Co-author DOI 10.1016/j.canlet.2018.11.007↗
  19. Thymidine kinase 1 silencing retards proliferative activity of pancreatic cancer cell via E2F1-TK1-P21 axis. Co-author DOI 10.1111/cpr.12428↗
  20. Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase reg… Co-author DOI 10.1186/s12943-017-0619-6↗
  21. miR-615-5p is epigenetically inactivated and functions as a tumor suppressor in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/onc.2014.101↗
  22. Overexpression of serine/threonine-protein kinase-1 in pancreatic cancer tissue: Serine/threonine-protein kinase-1 knockdown increases the chemosensitivity of … Co-author DOI 10.3892/mmr.2015.3434↗
  23. Elevation of MMP-9 and IDO induced by pancreatic cancer cells mediates natural killer cell dysfunction. Co-author DOI 10.1186/1471-2407-14-738↗
  24. Persistent activation of pancreatic stellate cells creates a microenvironment favorable for the malignant behavior of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.27715↗
  25. MAP3K10 promotes the proliferation and decreases the sensitivity of pancreatic cancer cells to gemcitabine by upregulating Gli-1 and Gli-2. Co-author DOI 10.1016/j.canlet.2012.11.005↗
  26. miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2. Co-author DOI 10.3892/or.2013.2297↗

Trials 1

  1. NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line Treatment of Locally Advanced Pancreati… Study director NCT06494514↗

Closest collaborators

The 25 strongest of 114 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kuirong Jiang · 17 shared papers, 2013–2026 · strength 2.42
  2. Jishu Wei · 15 shared papers, 2013–2026 · strength 1.89
  3. Wentao Gao · 12 shared papers, 2013–2026 · strength 1.55
  4. Yi Miao · 15 shared papers, 2013–2025 · strength 1.50
  5. Junli Wu · 9 shared papers, 2013–2026 · strength 1.27
  6. Zipeng Lu · 9 shared papers, 2013–2026 · strength 1.09
  7. Lingdi Yin · 7 shared papers, 2018–2026 · strength 1.01
  8. Yunpeng Peng · 6 shared papers, 2014–2025 · strength 0.69
  9. Juan Du · 1 shared trial, 2024 · strength 0.68
  10. Yang Feng Wu · 3 shared papers, 2024–2025 · strength 0.68
  11. Chunhua Xi · 6 shared papers, 2017–2024 · strength 0.67
  12. Kai Zhang · 4 shared papers, 2021–2024 · strength 0.55
  13. Kuirong Jiang · 4 shared papers, 2013–2025 · strength 0.53
  14. Qianqian Wang · 2 shared papers, 2025 · strength 0.50
  15. Dong Xu · 2 shared papers, 2025 · strength 0.50
  16. Chaozhi Yang · 3 shared papers, 2021–2022 · strength 0.42
  17. Chenjie Qiu · 3 shared papers, 2021–2022 · strength 0.42
  18. Nan Lyu · 2 shared papers, 2024–2026 · strength 0.42
  19. Yi Miao · 3 shared papers, 2013–2025 · strength 0.42
  20. Kai Zhang · 2 shared papers, 2022–2026 · strength 0.40
  21. Kai Zhang · 2 shared papers, 2021–2025 · strength 0.39
  22. Jian‐Min Chen · 4 shared papers, 2013–2025 · strength 0.36
  23. Qiang Li · 4 shared papers, 2013–2022 · strength 0.34
  24. Xumin Huang · 2 shared papers, 2020–2026 · strength 0.34
  25. Kai Lin · 2 shared papers, 2021–2022 · strength 0.29

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.